Skip to search formSkip to main contentSkip to account menu

APO 866

Known as: APO-866, APO866, NMPRTase Inhibitor APO866 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DaporinadEnzyme Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
APO866 Not Effective for Cutaneous T-Cell Lymphoma
The injectable drug APO866, designed to induce apoptosis, did not have efficacy against cutaneous T-cell lymphoma, according to… 
2011
2011
against hematologic malignancies The NAD biosynthesis inhibitor APO866 has potent antitumor activity
2010
2010
Abstract 5220: Early prediction of tumor response to APO866 treatment with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in human ovary cancer xenografts in mice
Introduction: APO866 is a new anti-tumor compound found to inhibit nicotinamide phosphoribosyltransferase (NAMPT), an enzyme… 
2009
2009
Response: NAD targeting efficiently kills hematologic cancer cells
Response We thank Cea and coauthors for sharing their results on APO866 activity in hematologic malignancies. We reported that… 
2008
2008
Selective inhibition of PBEF activity with a small molecule inhibitor, APO866 ameliorates collagen-induced arthritis [Abstract]
2007
2007
Antitumor efficacy of APO866 against Myla-2059, a model of cutaneous t-cell lymphoma
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 5610 APO866 (formerly FK866), an inhibitor of the enzyme nicotinamide…